[
    [
        {
            "time": "",
            "original_text": "贝达药业一边赴港上市，实控人一边减持超2亿元 减持股份",
            "features": {
                "keywords": [
                    "贝达药业",
                    "赴港上市",
                    "减持",
                    "实际控制人"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业一边赴港上市，实控人一边减持超2亿元 减持股份",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：公司尚未开展埃克替尼和贝伐单抗的联合用药注册性临床研究",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "贝伐单抗",
                    "联合用药",
                    "临床研究"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业：公司尚未开展埃克替尼和贝伐单抗的联合用药注册性临床研究",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "新药进展 | 贝达药业第四代EGFR抑制剂获批临床，用于治疗非小细胞肺癌",
            "features": {
                "keywords": [
                    "贝达药业",
                    "第四代EGFR抑制剂",
                    "获批临床",
                    "非小细胞肺癌"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "新药进展 | 贝达药业第四代EGFR抑制剂获批临床，用于治疗非小细胞肺癌",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "电鳗快报 | “集采”抗肿瘤药降价超六成 这两药企的窘境如何化解？",
            "features": {
                "keywords": [
                    "集采",
                    "抗肿瘤药",
                    "降价",
                    "药企窘境"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "电鳗快报 | “集采”抗肿瘤药降价超六成 这两药企的窘境如何化解？",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "速递！杨森达成两项战略合作；贝达1类新药在美获批；FDA扩大君实/礼来双抗疗法紧急使用授权",
            "features": {
                "keywords": [
                    "贝达药业",
                    "1类新药",
                    "美国获批",
                    "杨森",
                    "战略合作",
                    "FDA",
                    "君实/礼来",
                    "双抗疗法"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "速递！杨森达成两项战略合作；贝达1类新药在美获批；FDA扩大君实/礼来双抗疗法紧急使用授权",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]